Funded Projects › FP7
STREPSYNTH · Rewiring the Streptomyces cell factory for cost-effective production of biomolecules
STREPSYNTH aims to set-up a Streptomyces-based new industrial production platform (SNIP) for high value added biomolecules. Streptomyces lividans was chosen as a bacterial host cell because it has been already shown to be highly efficient for the extracellular production of a number of heterologous molecules that vary chemically, has a robust tradition of industrial fermentation and is fully accessible to genetic intervention. To develop SNIP our strategy has two components: first, we will construct a collection of reduced-genome S. lividans strains. This will metabolically streamline the cell and rid it of agents (e.g. proteases) of potential harm to the heterologous polypeptides. Second, we will engineer synthetic parts and cassettes, i.e. reshuffled, rewired and repurposed genetic elements either indigenous to S. lividans or heterologous genes organized in artificial operon clusters. These elements will serve three aims: transcriptional and translational optimization, sophisticated on-demand transcriptional regulation that will provide unique fermentation control and metabolic engineering of complete cellular pathways channeling biomolecules to profuse extracellular secretion. Synthetic parts and cassettes will be either directly incorporated into the genome or be hosted in the form of plasmids. Systems biology tools will guide fine-tuning rounds of cell factory engineering and fermentation optimization. To set up SNIP we chose two classes of biomolecules with obvious immediate industrial value and application: heterologous proteins (industrial enzymes, biopharmaceuticals, biofuel enzymes, diagnostics) and small molecules (lantipeptides and indolocarbozoles) useful for multiple industrial purposes (biopharmaceuticals, additives, food technology, bioenergy). These biomolecules are of immediate interest to SMEs that participate and guide the industrial relevance of STREPSYNTH. SNIP is a modular platform that can be repurposed for diverse future applications.
Consortium · 17 organisations
KATHOLIEKE UNIVERSITEIT LEUVEN
BE · €1,643,099
PROGENUS SA
BE · €463,700
THE UNIVERSITY OF MANCHESTER
UK · €320,223
ENTRECHEM SL
ES · €596,450
FORSCHUNGSZENTRUM JULICH GMBH
DE · €264,031
PHARMABIOTEC GMBH
DE · €128,808
UNIVERSITAT WIEN
AT · €425,490
Q-BIOLOGICALS NV
BE · €1,042,070
IDRYMA TECHNOLOGIAS KAI EREVNAS
EL · €251,170
MATIS OHF
IS · €280,290
USTAV MOLEKULARNEJ BIOLOGIE SLOVENSKEJ AKADEMIE VIED
SK · €183,680
TECHNISCHE UNIVERSITAT BERLIN
DE · €777,550
HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH
DE · €594,794
TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY
IL · €481,650
UNIVERSITAET BIELEFELD
DE · €578,500
NORGES TEKNISK-NATURVITENSKAPELIGE UNIVERSITET NTNU
NO · €353,115
APRONEX S.R.O
CZ · €306,450
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.